Investors of Aardvark Therapeutics Have a Chance to Lead Class Action Lawsuit

Aardvark Therapeutics Faces Class Action Lawsuit

Aardvark Therapeutics, Inc. (NASDAQ: AARD), a clinical-stage biopharmaceutical firm, is currently under scrutiny as investors grapple with significant losses due to recent developments in the company's clinical trials and regulatory dealings. The firm Hagens Berman Sobol Shapiro LLP is notifying affected investors of their opportunity to lead a class action lawsuit against Aardvark before the imminent October 13 deadline.

Context of the Lawsuit

The legal action relates to Aardvark's initial public offering (IPO), which took place on February 13, 2025, along with subsequent securities transactions until May 14, 2026. Investors who purchased stocks or other securities during this time are encouraged to come forward. Reports indicate that Aardvark’s offering documents may have contained misleading statements regarding its promising drug candidate, ARD-101, which targets bitter taste receptors to treat hyperphagia linked to Prader-Willi Syndrome (PWS).

Central to the allegations of the lawsuit is the claim that Aardvark did not adequately disclose vital information about ARD-101's safety and efficacy—specifically that it was much less safe than the company had implied. Evidence suggests that during trials, unexpected reversible cardiac effects were noted at higher doses of the drug, a fact that was not fully communicated to investors.

Key Events Leading Up to the Lawsuit

The situation escalated for Aardvark in 2026, when on February 27, the company announced a voluntary pause of its Phase 3 HERO trial, citing troubling cardiac observations from routine safety checks in healthy participants. Following this announcement, the company's stock saw a dramatic drop of over 56%. The fallout continued on May 14, when the U.S. Food and Drug Administration (FDA) imposed a full clinical hold on Aardvark's investigational new drug application for ARD-101, affecting all ongoing studies, including the HERO trial. This action led to an additional 32.1% decline in Aardvark's stock price.

Hagens Berman's Investigation

Marking the importance of shareholders' rights, Reed Kathrein, a leading partner at Hagens Berman, emphasized the necessity of the lawsuit, noting that Aardvark's alleged misrepresentation regarding the drug's prospects could have serious legal and financial implications. The investigation revolves around whether Aardvark’s management knowingly misled investors regarding the status and safety of ARD-101.

Actions for Affected Investors

Investors who have encountered losses related to Aardvark's securities and wish to act must do so by the court's October 13 deadline to seek the status of Lead Plaintiff in the class action. The firm is extending invitations to affected investors to discuss their potential recovery options. For anyone with additional information regarding Aardvark Therapeutics, whistleblowing opportunities may be available as well, potentially yielding rewards for participants in the investigation by the SEC.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is a renowned firm specializing in shareholder rights litigation, known for holding corporations accountable and achieving substantial settlements for harmed investors. With over $2.9 billion secured through various legal actions, the firm asserts its commitment to justice for investors and other affected parties. More information can be found on its website, where interested parties can find resources and seek counsel regarding their claims.

For those interested in pursuing action against Aardvark Therapeutics, they can reach out to Hagens Berman by phone or email, assembling a robust response to the ongoing issues surrounding this pharmaceutical entity.